ESR1 and breast carcinoma: PF-07248144 is the KAT6A/KAT6B inhibitor currently in clinical trials, and the results from the phase 1 clinical trial were recently published and showed durable antitumor effects in metastatic ER-positive HER2-negative breast cancer [58].